Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2014; 20(39): 14479-14487
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14479
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14479
Evaluation of “top-down” treatment of early Crohn’s disease by double balloon enteroscopy
Rong Fan, Jie Zhong, Zheng-Ting Wang, Shu-Yi Li, Jie Zhou, Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Yong-Hua Tang, Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Author contributions: Fan R contributed partially to conception and design of the study, collection, analysis and interpretation of the data, and drafting of the article; Zhong J contributed to design of the study and endoscopic evaluation and revised the article critically for important intellectual content; Wang ZT participated in design of the study; Zhou J participated in collection of the data; Li SY participated in collection and analysis of the data; Tang YH contributed to radiologic evaluation.
Correspondence to: Jie Zhong, MD, PhD, Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, China. jimmyzj64@medmail.com.cn
Telephone: +86-21-64370045 Fax: +86-21-64315951
Received: November 10, 2013
Revised: March 16, 2014
Accepted: June 20, 2014
Published online: October 21, 2014
Revised: March 16, 2014
Accepted: June 20, 2014
Published online: October 21, 2014
Core Tip
Core tip: We assessed the outcome of “top-down” treatment in terms of deep remission in treatment-naïve patients with early Crohn’s disease (CD) with small bowel involvement. This study is believed to be the first designed with deep remission as the primary endpoint. Furthermore, mucosal healing was assessed by double balloon enteroscopy for the first time in patients with CD treated with biologic agents. We excluded patients with luminal fibrostenotic or abdominal fistulizing CD in screening, resulting in encouraging deep remission rates at week 30. These results may have implications in the treatment of CD.